CD274 and non-small cell lung carcinoma: Additionally, pembrolizumab, durvalumab (a PD-L1 inhibitor), and nivolumab have been associated with positive results in the perioperative NSCLC setting of the KEYNOTE-671, AEGEAN, and CheckMate 77T trials, respectively, with KEYNOTE-671 recently showing an OS benefit [24,25,26,27].